Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.51 +0.28 (+1.16%)
Official Closing Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%
Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 trial. 
Via Benzinga
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma
 
Via Benzinga
P/E Ratio Insights for Pfizer
 
Via Benzinga
How Do Investors Really Feel About Pfizer?
 
Via Benzinga
2 Large-Cap Stocks to Target This Week and 1 to Keep Off Your Radar
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an... 
Via StockStory
Hearing Against Pfizer Set For 30 May In Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen By Levin Papantonio
From Levin Papantonio
Via Business Wire
Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children
RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed. 
Via Benzinga
Is Pfizer Stock a Buy After This $1.25 Billion Investment?
Via The Motley Fool
Down 63%, Should You Buy the Dip on Pfizer?
Pfizer has taken its lumps lately. It's time to wonder whether the stock can make a comeback. 
Via The Motley Fool
Topics Economy Government World Trade
1 Ultra-High-Yield Dividend Stock Down 57% to Buy Hand Over Fist
Via The Motley Fool
Topics Government Intellectual Property World Trade
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result
There's little doubt these pharmaceutical companies' costs will soon be rising at least a little. 
Via The Motley Fool
Topics Government Supply Chain World Trade
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
Pfizer's high dividend yield warrants scrutiny regarding its sustainability, given changing revenues and pipeline investments. 
Via MarketBeat
Pfizer Stock Analysis: Buy, Sell, or Hold?
Via The Motley Fool
3 Stocks Under $10 Skating on Thin Ice
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be... 
Via StockStory
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
FDA Limits Annual COVID-19 Boosters To High-Risk Americans, Demands New Trials For Healthy Adults In Policy Shift Under RFK Jr.
The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter... 
Via Benzinga
2 High-Yield Dividend Stocks to Buy Right Now
Via The Motley Fool
Topics Earnings Intellectual Property
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Topics Economy Law Enforcement
Stay informed about the most active stocks in the S&P500 index on Tuesday's session.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention. 
Via Chartmill
Pfizer Stock Is Trading Higher Tuesday: What's Going On?
Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on. 
Via Benzinga
FDA Sets New Guidelines For Approving COVID-19 Booster Shots In Healthy Individuals: Moderna, Novavax Stocks Rise
The agency plans to demand stronger evidence of efficacy for the shots before approval is granted for healthy persons, between the ages of six months and 64 years, with no risk factors for severe... 
Via Stocktwits
The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped.
The new framework limits future Covid shots to people age 65 and older and those six months and older with a risk factor for serious illness. 
Via Investor's Business Daily
Topics Bankruptcy Government
WeRide Teams Up With Tencent Cloud To Accelerate Global Robotaxi Ambitions
The company said Tencent Cloud will allow it to offer localized and compliant cloud services in countries outside of China, accelerating the commercial rollout of its robotaxi services overseas. 
Via Stocktwits
Topics Supply Chain
Pfizer Strikes Deal With China’s 3SBio For Experimental Cancer Drug License
3SBio’s experimental cancer drug is currently undergoing clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. 
Via Stocktwits
Topics Government
Sell-Off Grips Dalal Street: Nifty Ends Below 24,700; Metals Shine On China Rate Cut
Indian markets ended sharply lower, dragged by broad-based profit booking, FPI outflows, and fading optimism over the U.S.-India trade deal. 
Via Stocktwits
Topics Economy
These 3 Dividend Stocks Yield More Than 6% and Their Payouts Look Safe
Via The Motley Fool
Topics Intellectual Property
Pfizer Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Deal
Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody SSGJ-707. 
Via Benzinga
Retail Bulls Cheer FDA Clearance For BrainStorm’s ALS Therapy, But Shares Dip After Hours
BrainStorm Cell Therapeutics plans to enroll 200 ALS patients in its FDA-cleared Phase 3b trial of NurOwn, with a 24-week double-blind phase followed by an open-label extension. 
Via Stocktwits
Topics Intellectual Property
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.